You are here: Industry Insights > msd

News List

MSD and Crick Institute partner on motor neurone disease research pharmaceutical-technology
August 23, 2019
MSD, known as Merck in the US and Canada, has partnered with the Francis Crick Institute to gain better insight into the causes of motor neurone disease or amyotrophic lateral sclerosis (ALS).
‘Unprecedented’ results in AZ’ late-stage Lynparza trial pharmatimes
June 05, 2019
New data from a Phase III trial of AstraZeneca and MSD’s Lynparza (olaparib) has shown that 22% of patients receiving the monotherapy remained free of disease progression after two years vs. 10% on placebo, making the drug the first PARP inhibitor to demo
NICE recommends Prevymis on the NHS after re-evaluation europeanpharmaceuticalreview
June 05, 2019
The National Institute for Health and Care Excellence is recommending MSD’s Prevymis (letermovir) within the NHS.
NICE recommendation for MSD’s Prevymis after re-evaluation pharmatimes
June 03, 2019
Document, recommending MSD’s Prevymis (letermovir) for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) within the NHS.
MSD’s Keytruda falls short in late stage breast cancer study pharmatimes
May 21, 2019
MSD has announced that its anti-PD-1 therapy Keytruda has failed to meet its primary endpoint in a late-stage study testing the drug as a standalone treatment in patients with metastatic triple-negative breast cancer (TNBC).
MSD's Keytruda recommended on NHS in Scotland for Stage 3 melanoma pharmafile
May 15, 2019
MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) decided to ...
Five hepatitis C drugs to become available on the NHS pharmaceutical-technology
May 05, 2019
A deal signed by pharmaceutical companies AbbVie, Gilead Sciences and Merck Sharp and Dohme (MSD) will see five new hepatitis C drugs become available on the UK National Health Service (NHS).
Tessa Therapeutics collaborates with MSD to treat Cervical Cancer biospectrumasia
April 16, 2019
The collaboration will evaluate the safety and efficacy of Tessa's armored human papillomavirus-specific T cell (HPVST) therapy combined with MSD's……
Lynparza gains EU approval for type of metastatic breast cancer pharmatimes
April 11, 2019
AstraZeneca and MSD‘s Lynparza (olaparib) has been approved by the European Commission for the treatment of germline BRCA-mutated HER2-negative metastatic breast cancer.
Lynparza gets FDA approval for ovarian cancer pharmatimes
December 21, 2018
AstraZeneca and MSD have announced that Lynparza (olaparib) has been given the green light by the FDA for first-line maintenance therapy of BRCA-mutated advanced ovarian cancer, further expanding the drug's reach.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page